Skip to main content

Bristol Myers doubles down on Immatics with new $770M biobucks collab for solid tumor bispecific: Fiercebiotech

 Bristol Myers Squibb is doubling down on Immatics with $150 million upfront to get access to a preclinical bispecific targeting solid tumors.

This will be the pair's second collaboration, technically speaking. Immatics inked a deal with Celgene in August 2019 prior to its acquisition by BMS. That collaboration is focused on T-cell therapies for solid tumors and is still in the preclinical phase.

Now, BMS is putting up $150 million and could dole out up to another $770 million in biobucks to the German biotech to license, develop and commercialize a T cell-redirecting, or TCR, bispecific, the companies said Tuesday. Immatics asked German regulators last month to approve a clinical trial of the drug, dubbed IMA401, in various solid tumors that is slated to begin in the first half of next year.


Immatics retains the option to co-fund U.S. development of IMA401 in return for enhanced U.S. royalty payments and/or will co-promote the medicine in the U.S. 

The bispecific, as its name suggests, has two core goals: One binding region targets melanoma-associated antigen 4 and/or 8 (MAGEA4/8), and the other region aims to engage and activate T cells. MAGEA4/8 is prevalent in a slate of solid tumors across the lungs, head and neck, bladder and uterus, among other areas of the body.


IMA401 is the most advanced therapy in Immatics' TCR bispecific pipeline, the biotech said. These therapies have a "cell therapy-like efficacy in an off-the-shelf platform," according to BMS' Teri Foy, Ph.D., senior vice president of research and early development for immuno-oncology and cell therapy. 

In preclinical studies, IMA401 showed anti-tumor activity, according to Immatics. Under the deal, the two companies will collaborate on clinical development. 

The Big Pharma tie-up comes a month after Immatics released data on the TCR-engineered cell therapy IMA203 that showed responses in 50% of heavily pretreated patients. But many patients saw their cancer come back within weeks, which means Immatics need to improve durability to have a shot at the market


https://www.fiercebiotech.com/biotech/immatics-inks-new-770m-biobucks-collab-bristol-myers-for-preclinical-solid-tumor-bispecific


Comments

Popular posts from this blog

Pfizer said an updated version of its COVID-19 vaccine will be 'ready in 100 days' if the new Omicron variant is resistant to its current vaccine

  Pfizer said it will be able to manufacture and distribute an updated version of its COVID-19 vaccine within 100 days if the new variant Omicron is found to be resistant to its current vaccine.  Scientists first detected the new variant in South Africa. It has since spread to several other countries, including Israel and Belgium, prompting  a spate of travel restrictions  across Europe, Asia, and  North America , Insider's Aria Bendix  reported . A health official said on Saturday that two cases of the variant have been  detected in the UK . The variant itself has multiple mutations that might make it easier for it to evade antibodies that developed in the body after receiving a COVID-19 vaccine. The mutations might also cause the variant to spread easily —  even among vaccinated people .  The World Health Organization has labeled Omicron a " variant of concern ," a distinction given to the most threatening coronavirus variants. Delta, the v...

Texas governor bans vaccine passports from being required in state ABC News

  Thats Right States like Texas and Florida got the Vaccine Passport Conspiracy from Del Bigtree.  https://abc7.com/politics/texas-governor-bans-vaccine-passport-requirement-in-state/10491161/ AUSTIN, Texas -- Gov. Greg Abbott issued an executive order Tuesday morning prohibiting state agencies or political subdivisions in Texas from creating a "vaccine passport" requirement. Conversation has grown around  vaccine passports recently as an option that can be used for travel or even eating out . They are typically described as an app with a code that verifies if someone has been vaccinated or recently tested negative for COVID-19. They're already in use in Israel, and in development in parts of Europe. But Abbott shut that down as an option in the Lone Star State with Executive Order No. GA - 35 also prohibiting "organizations receiving public funds from requiring consumers to provide documentation of vaccine status in order to receive any service or enter any place....

Close the Gap Foldit